share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  09/12 16:19

Moomoo AI 已提取核心信息

On September 10, 2024, 180 Life Sciences Corp. announced the resignation of its Chief Financial Officer (CFO) and Secretary, Mr. Ozan Pamir, effective September 30, 2024. The resignation was not due to any disagreements with the company's operations, policies, or practices. Following this, on September 11, 2024, the Board appointed Mr. Omar Jimenez, a current board member, as the new CFO and Secretary, with his tenure beginning on September 30, 2024. Mr. Jimenez's qualifications and experience are detailed in the company's Annual Report filed on April 29, 2024. In conjunction with his new role, Mr. Jimenez will resign from his positions on the Company’s Compensation Committee, Nominating and Corporate Governance Committee, and as Chairman of the Audit Committee. The company plans to add new independent board members to fill these committees in the coming weeks. A press release on September 12, 2024, officially disclosed Mr. Jimenez's appointment. 180 Life Sciences Corp. is a clinical-stage biotechnology company focusing on developing treatments for chronic pain, inflammation, and fibrosis.
On September 10, 2024, 180 Life Sciences Corp. announced the resignation of its Chief Financial Officer (CFO) and Secretary, Mr. Ozan Pamir, effective September 30, 2024. The resignation was not due to any disagreements with the company's operations, policies, or practices. Following this, on September 11, 2024, the Board appointed Mr. Omar Jimenez, a current board member, as the new CFO and Secretary, with his tenure beginning on September 30, 2024. Mr. Jimenez's qualifications and experience are detailed in the company's Annual Report filed on April 29, 2024. In conjunction with his new role, Mr. Jimenez will resign from his positions on the Company’s Compensation Committee, Nominating and Corporate Governance Committee, and as Chairman of the Audit Committee. The company plans to add new independent board members to fill these committees in the coming weeks. A press release on September 12, 2024, officially disclosed Mr. Jimenez's appointment. 180 Life Sciences Corp. is a clinical-stage biotechnology company focusing on developing treatments for chronic pain, inflammation, and fibrosis.
在2024年9月10日,180 Life Sciences Corp.宣布其首席财务官(CFO)兼秘书Ozan Pamir先生辞职,辞职日期为2024年9月30日。这一辞职并非由于与公司运营、政策或做法的任何分歧。随后,在2024年9月11日,董事会任命现任董事会成员Omar Jimenez先生为新任CFO兼秘书,其任期将于2024年9月30日开始。Jimenez先生的资格和经验详见公司于2024年4月29日提交的年度报告。为了担任新职务,Jimenez先生将辞去公司薪酬委员会、提名和公司治理委员会的职务,并辞去审计委员会主席职务。公司计划在未来几周内增加新的独立董事来填补这些委员会。2024年9月12日的新闻稿正式宣布了Jimenez先生的任命。180 Life Sciences Corp.是一家临床阶段的生物技术公司,专注于开发治疗慢性疼痛、炎症和纤维化的药物。
在2024年9月10日,180 Life Sciences Corp.宣布其首席财务官(CFO)兼秘书Ozan Pamir先生辞职,辞职日期为2024年9月30日。这一辞职并非由于与公司运营、政策或做法的任何分歧。随后,在2024年9月11日,董事会任命现任董事会成员Omar Jimenez先生为新任CFO兼秘书,其任期将于2024年9月30日开始。Jimenez先生的资格和经验详见公司于2024年4月29日提交的年度报告。为了担任新职务,Jimenez先生将辞去公司薪酬委员会、提名和公司治理委员会的职务,并辞去审计委员会主席职务。公司计划在未来几周内增加新的独立董事来填补这些委员会。2024年9月12日的新闻稿正式宣布了Jimenez先生的任命。180 Life Sciences Corp.是一家临床阶段的生物技术公司,专注于开发治疗慢性疼痛、炎症和纤维化的药物。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息